Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS Biol. 2014 Aug 5;12(8):e1001923. doi: 10.1371/journal.pbio.1001923. eCollection 2014.

Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease.

Author information

  • 1Child Study Center, Yale University, New Haven, Connecticut, United States of America.
  • 2Department of Chemistry, Yale University, New Haven, Connecticut, United States of America.
  • 3Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, United States of America.
  • 4Child Study Center, Yale University, New Haven, Connecticut, United States of America; Laboratory for Drug Discovery in Neurodegeneration and Department of Neurology, Brigham and Women's Hospital, Cambridge, Massachusetts, United States of America.
  • 5Laboratory for Drug Discovery in Neurodegeneration and Department of Neurology, Brigham and Women's Hospital, Cambridge, Massachusetts, United States of America.
  • 6Child Study Center, Yale University, New Haven, Connecticut, United States of America; Department of Laboratory Medicine, Yale University, New Haven, Connecticut, United States of America.
  • 7Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York, United States of America.
  • 8Infectious and Inflammatory Disease Center, Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America.
  • 9Department of Psychiatry, Yale University, New Haven, Connecticut, United States of America.
  • 10Child Study Center, Yale University, New Haven, Connecticut, United States of America; Department of Psychiatry, Yale University, New Haven, Connecticut, United States of America; Department of Neurobiology, Yale University, New Haven, Connecticut, United States of America.

Abstract

STEP (STriatal-Enriched protein tyrosine Phosphatase) is a neuron-specific phosphatase that regulates N-methyl-D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking, as well as ERK1/2, p38, Fyn, and Pyk2 activity. STEP is overactive in several neuropsychiatric and neurodegenerative disorders, including Alzheimer's disease (AD). The increase in STEP activity likely disrupts synaptic function and contributes to the cognitive deficits in AD. AD mice lacking STEP have restored levels of glutamate receptors on synaptosomal membranes and improved cognitive function, results that suggest STEP as a novel therapeutic target for AD. Here we describe the first large-scale effort to identify and characterize small-molecule STEP inhibitors. We identified the benzopentathiepin 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (known as TC-2153) as an inhibitor of STEP with an IC50 of 24.6 nM. TC-2153 represents a novel class of PTP inhibitors based upon a cyclic polysulfide pharmacophore that forms a reversible covalent bond with the catalytic cysteine in STEP. In cell-based secondary assays, TC-2153 increased tyrosine phosphorylation of STEP substrates ERK1/2, Pyk2, and GluN2B, and exhibited no toxicity in cortical cultures. Validation and specificity experiments performed in wild-type (WT) and STEP knockout (KO) cortical cells and in vivo in WT and STEP KO mice suggest specificity of inhibitors towards STEP compared to highly homologous tyrosine phosphatases. Furthermore, TC-2153 improved cognitive function in several cognitive tasks in 6- and 12-mo-old triple transgenic AD (3xTg-AD) mice, with no change in beta amyloid and phospho-tau levels.

PMID:
25093460
[PubMed - indexed for MEDLINE]
PMCID:
PMC4122355
Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk